159 related articles for article (PubMed ID: 10880728)
1. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
2. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
3. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
4. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
5. First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YA; Zhou BT
J Pharm Pharm Sci; 2015; 18(3):256-65. PubMed ID: 26517132
[TBL] [Abstract][Full Text] [Related]
6. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
7. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
[TBL] [Abstract][Full Text] [Related]
9. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.
Antunes NJ; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Marques MP; Lanchote VL
J Pharm Biomed Anal; 2018 Feb; 149():442-447. PubMed ID: 29169112
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Maschio M; Albani F; Jandolo B; Zarabla A; Contin M; Dinapoli L; Fabi A; Pace A; Baruzzi A
J Neurooncol; 2008 Nov; 90(2):217-21. PubMed ID: 18612799
[TBL] [Abstract][Full Text] [Related]
15. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad A; Garnett WR
Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
[TBL] [Abstract][Full Text] [Related]
17. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
18. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
19. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
